Testing BTX-9341 for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be hormone receptor-positive (HR+) and HER2-negative.
- You must have had no more than one chemotherapy treatment for advanced or metastatic breast cancer.
- You must have received a CDK4/6 inhibitor (like palbociclib, ribociclib, or abemaciclib) in the past.
- Your blood cell counts, liver function, and kidney function must be within acceptable limits.
- You cannot have brain metastases, a known RB1 gene mutation, or bleeding disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a new drug (RGT-419B), given alone or with hormone (endocrine) therapy, in people with advanced ER-positive, HER2-negative breast cancer that has progressed after standard treatments. It looks mainly at safety and early signs of how well the treatment may work.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This trial tests a new pill (M1774) combined with a hormone therapy called fulvestrant for people with advanced hormone-receptor-positive, HER2-negative breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. The study focuses on people with certain genetic markers in their tumor, hoping the combination will work better than current options.
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This trial tests a new drug combination (SYS6023) for advanced breast cancer that has spread or cannot be surgically removed. The treatment targets a protein called HER3, which may help stop cancer growth in patients whose cancer has progressed despite previous treatments.
This trial tests an experimental drug called HLX43, given alone or with other immune-boosting drugs, for people with advanced triple-negative breast cancer (a type of breast cancer that does not have the common hormone receptors). The goal is to see if this drug can shrink tumors or slow cancer growth.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.